EECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONTEXT

J.L. Huicochea-Bartelt; X. Burbano; E. Palacios; S. Herran; C. Valencia

doi:10.1016/j.jval.2015.03.1179

EECONOMIC EVALUATION OF AFATINIB AS THE FIRST LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) LOCALLY ADVANCED OR METASTATIC IN PRESENCE OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATIONS IN A MEXICAN INSTITUTIONAL CONTEXT

Value in Health ◽

10.1016/j.jval.2015.03.1179 ◽

2015 ◽

Vol 18 (3) ◽

pp. A307

Author(s):

J.L. Huicochea-Bartelt ◽

X. Burbano ◽

E. Palacios ◽

S. Herran ◽

C. Valencia

Keyword(s):

Locally Advanced ◽

Growth Factor Receptor ◽

Institutional Context ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

PCN136 Cost-Effectiveness Analysis of Dacomitinib Versus Gefitinib for the First-line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR)-Activating Mutations in Portugal

Value in Health ◽

10.1016/j.jval.2020.08.273 ◽

2020 ◽

Vol 23 ◽

pp. S447

Author(s):

L. Silva Miguel ◽

A.T. Paquete ◽

J. Alarcão ◽

R. Guerreiro ◽

M. Inês ◽

...

Keyword(s):

Locally Advanced ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Activating Mutations ◽

Effectiveness Analysis ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

Therapeutic Advances in Medical Oncology ◽

10.1177/1758834010370698 ◽

2010 ◽

Vol 2 (5) ◽

pp. 301-307 ◽

Cited By ~ 18

Author(s):

Isamu Okamoto ◽

Tetsuya Mitsudomi ◽

Kazuhiko Nakagawa ◽

Masahiro Fukuoka

Keyword(s):

Lung Cancer ◽

Growth Factor Receptor ◽

Small Cell ◽

Egfr Mutations ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene

Malignant tumours ◽

10.18027/2224-5057-2015-4-35-47 ◽

2015 ◽

pp. 35 ◽

Cited By ~ 1

Author(s):

Vera Andreevna Gorbunova ◽

Sergey Vladimirovich Orlov ◽

Sergey Kensarinovich Zyryanov ◽

Dmitriy Yuryevich Belousov

Keyword(s):

Lung Cancer ◽

Pharmacoeconomic Analysis ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Egfr Gene ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Overall survival (OS) of real-world patients with stage IIIb/IV non-small cell lung cancer (NSCLC) initiating epidermal growth factor receptor (EGFR) targeted tyrosine kinase inhibitors (TKI) as first-line treatment in England

Lung Cancer ◽

10.1016/s0169-5002(19)30138-2 ◽

2019 ◽

Vol 127 ◽

pp. S40

Author(s):

U. Rigney ◽

K. Lock ◽

C. Chen ◽

C. Escriu

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Kinase Inhibitors ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0 study)

Translational Lung Cancer Research ◽

10.21037/tlcr.2019.11.19 ◽

2019 ◽

Vol 8 (6) ◽

pp. 1086-1090

Author(s):

Yusuke Chihara ◽

Tadaaki Yamada ◽

Junji Uchino ◽

Nobuyo Tamiya ◽

Yoshiko Kaneko ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Trial ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 43

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.7012 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 7012-7012 ◽

Cited By ~ 9

Author(s):

R. Rosell ◽

C. Daniel ◽

R. Ramlau ◽

A. Szczesna ◽

M. Constenla ◽

...

Keyword(s):

Lung Cancer ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Randomized Phase Ii ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7537 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7537-7537 ◽

Cited By ~ 7

Author(s):

T. Mok ◽

D. R. Spigel ◽

K. Park ◽

M. A. Socinski ◽

S. Y. Tung ◽

...

Keyword(s):

Lung Cancer ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Efficacy And Safety ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non–Small-Cell Lung Cancer andEGFRMutations?

Journal of Clinical Oncology ◽

10.1200/jco.2013.52.8794 ◽

2014 ◽

Vol 32 (8) ◽

pp. 859-863 ◽

Cited By ~ 2

Author(s):

Eva R. Haspinger ◽

Marina Chiara Garassino ◽

Valter Torri ◽

Michela Cinquini ◽

Filippo De Braud ◽

...

Keyword(s):

Lung Cancer ◽

Receptor Tyrosine Kinase ◽

Kinase Inhibitor ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text

9123 POSTER Final Results of a Phase II Study of Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Non-small Cell Lung Cancer – Gefitinib for Elderly Patients With Lung Adenocarcinoma

European Journal of Cancer ◽

10.1016/s0959-8049(11)72435-2 ◽

2011 ◽

Vol 47 ◽

pp. S630

Author(s):

K. Asami ◽

T. Koizumi ◽

K. Hirai ◽

S. Ameshima ◽

A. Tsukadaira ◽

...

Keyword(s):

Lung Cancer ◽

Epidermal Growth Factor Receptor ◽

Phase Ii Study ◽

Growth Factor Receptor ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Epidermal Growth ◽

First Line Treatment

Download Full-text